Skip to main content

Medtronic Value Stock - Dividend - Research Selection

Medtronic

ISIN: IE00BTN1Y115 , WKN: A14M2J

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Medtronic plc manufactures and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. The company\'s Cardiac and Vascular Group segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; diagnostics and monitoring devices; mechanical circulatory support, TYRX, and AF products; and remote monitoring and patient-centered software. It also provides transcatheter heart valves, percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, peripheral vascular products, and products to treat superficial and deep venous diseases. Its Minimally Invasive Therapies Group segment offers surgical care, wound closure, electrosurgical, hernia mechanical device, mesh implant, ablation, interventional lung, ventilator, capnography, airway, sensor, monitor, compression, dialysis, enteral feeding, wound care, and medical surgical products; stapling, vessel sealing, fixation, and hardware instruments; and gastrointestinal, temperature management, inhalation therapy, and renal care solutions.

 

The company\'s Restorative Therapies Group segment offers products for spine, bone graft substitutes, biologic products, trauma, implantable neurostimulation therapies, and drug delivery systems for the treatment of chronic pain, movement disorders, obsessive-compulsive disorder, overactive bladder, urinary retention, fecal incontinence, and gastroparesis, as well as products to treat conditions of the ear, nose, and throat; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems; and therapies for vasculature in and around the brain. The company\'s Diabetes Group segment offers insulin pumps and consumables, continuous glucose monitoring systems, and Web-based therapy management software.

 

The company was founded in 1949 and is headquartered in Dublin, Ireland.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Medtronic SPR Therapeutics Deal Expands Pain Portfolio As Shares Screen Undervalued

2026-05-23
Medtronic (NYSE:MDT) has announced plans to acquire SPR Therapeutics to expand its neuromodulation and chronic pain management portfolio. The deal adds SPR's FDA cleared SPRINT Peripheral Nerve Stimulation System, a minimally invasive, non opioid option for chronic pain patients. This move is intended to strengthen Medtronic's position in the U.S. pain management market and broaden its range of therapies. Medtronic is a large medical device company with an established presence in...

Is It Time To Reconsider Medtronic (MDT) After Recent Share Price Weakness?

2026-05-23
With Medtronic stock trading at around US$78.60, this article walks through the key numbers so you can judge for yourself whether the current price offers fair value or a potential discount. Over shorter periods the stock has been mixed, up 3.2% over the last week, but down 5.6% over the last month and down 18.2% year to date. The 1 year return sits at 0.5% and the 3 year return at 6.4%, compared to a 27.7% decline over 5 years. Recent headlines around Medtronic have focused on its position...

Dexcom: A Medical Platform Play Gaining From AI, Not Disrupted By It

2026-05-22
Dexcom (DXCM) uses AI to boost margins and innovate CGM with Stelo for prediabetes.

11 'Safer' Dividend Dogs Lead 20 May Barron's 2026 Oil And Blue Chips

2026-05-22
Barron’s Oil & Blue Chip Tips for May 2026 highlight 20 stocks, with 11 deemed 'safer' based on free cash flow yields exceeding dividend yields. Read the full list here.

Deal Dispatch: IMAX Mulls Potential Sale, Shein Buys Everlane, West Marine Bankruptcy

2026-05-22
Major M&A deals this week include Cohere acquiring Reliant AI and Authentic Brands buys denim brand Lee. Bitcoin Depot announces bankruptcy.

Medtronic to create European software hub in Ireland

2026-05-22
The investment in cardiac digital health will add 85 jobs initially, with more growth expected over the next three years.

Medtech clinical trials navigate macro trends and regulatory changes

2026-05-22
The OCT Medical Devices conference will gather speakers to discuss opportunities in the medtech sector.

Future Dividend Kings - Part 1

2026-05-21
Dividend investing is a great thing for income-focused investors. Discover 8 companies that could become future Dividend Kings, comparing yields and dividend growth histories.

Cigna downgraded, Humana upgraded: Wall Street's top analyst calls

2026-05-20
Cigna downgraded, Humana upgraded: Wall Street's top analyst calls

Paroxysmal Supraventricular Tachycardia Market Analysis Report 2026-2036, Profiles of Leading Players - Medtronic, Boston Scientific, Abbott Laboratories, Milestone Pharmaceuticals, Sanofi, Pfizer

2026-05-21
The global Paroxysmal Supraventricular Tachycardia (PSVT) market is set for significant growth, driven by advancements in diagnostics and treatment, and rising cardiovascular awareness. Key factors include a surge in cardiovascular diseases, especially in the aging population, and increased use of minimally invasive techniques like catheter ablation. Emerging economies present ample opportunities, supported by improving healthcare infrastructure and preventive healthcare focus. Challenges persis